Vanguard Group Inc. Raises Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

Vanguard Group Inc. increased its position in shares of Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 10.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,182,512 shares of the company's stock after purchasing an additional 294,956 shares during the period. Vanguard Group Inc. owned 2.09% of Wave Life Sciences worth $39,368,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. State Street Corp increased its stake in Wave Life Sciences by 2.6% in the 3rd quarter. State Street Corp now owns 2,321,248 shares of the company's stock worth $19,034,000 after buying an additional 57,822 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Wave Life Sciences by 14.3% during the third quarter. Geode Capital Management LLC now owns 2,269,664 shares of the company's stock worth $18,615,000 after purchasing an additional 283,419 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in Wave Life Sciences by 8.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 914,469 shares of the company's stock valued at $11,312,000 after purchasing an additional 69,852 shares during the period. Moody Aldrich Partners LLC lifted its holdings in Wave Life Sciences by 31.5% in the 4th quarter. Moody Aldrich Partners LLC now owns 398,475 shares of the company's stock worth $4,929,000 after purchasing an additional 95,413 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in Wave Life Sciences by 19.3% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 387,871 shares of the company's stock worth $4,798,000 after purchasing an additional 62,862 shares during the period. Hedge funds and other institutional investors own 89.73% of the company's stock.

Wave Life Sciences Price Performance

Shares of NASDAQ:WVE traded down $0.10 during trading hours on Thursday, hitting $5.74. 133,962 shares of the company's stock traded hands, compared to its average volume of 1,137,932. The firm has a market capitalization of $881.01 million, a P/E ratio of -5.17 and a beta of -0.93. The business has a fifty day moving average price of $9.10 and a 200-day moving average price of $11.59. Wave Life Sciences Ltd. has a 1 year low of $4.25 and a 1 year high of $16.74.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last announced its quarterly earnings data on Tuesday, March 4th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.17) by $0.34. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%. The company had revenue of $83.75 million for the quarter, compared to the consensus estimate of $25.60 million. As a group, equities analysts predict that Wave Life Sciences Ltd. will post -1.14 earnings per share for the current year.

Analyst Ratings Changes

WVE has been the subject of a number of research reports. Jefferies Financial Group began coverage on shares of Wave Life Sciences in a research report on Tuesday, February 25th. They set a "buy" rating and a $26.00 target price for the company. Wedbush initiated coverage on Wave Life Sciences in a research report on Tuesday, April 8th. They set an "outperform" rating and a $18.00 price objective for the company. StockNews.com raised Wave Life Sciences from a "sell" rating to a "hold" rating in a report on Saturday, March 8th. Finally, HC Wainwright reissued a "buy" rating and set a $22.00 price target on shares of Wave Life Sciences in a research note on Wednesday, March 26th. Two analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $22.18.

Insider Buying and Selling

In other Wave Life Sciences news, Director Christian O. Henry sold 10,500 shares of Wave Life Sciences stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total transaction of $102,585.00. Following the completion of the sale, the director now directly owns 16,115 shares of the company's stock, valued at $157,443.55. The trade was a 39.45 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Paul Bolno sold 169,025 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $9.57, for a total value of $1,617,569.25. Following the transaction, the chief executive officer now directly owns 338,351 shares in the company, valued at $3,238,019.07. The trade was a 33.31 % decrease in their position. The disclosure for this sale can be found here. 29.10% of the stock is currently owned by insiders.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.